MedTrace Logo

Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer

NCT04986371 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-08-02

No results posted yet for this study

Summary

This is an open-label, single-arm, multi-center、non-interventional real-world study, which evaluate treatment pattern, safety and efficacy of Niraparib as first-line maintenance treatment for Chinese patient with newly diagnosed ovarian cancer , fallopian tube cancer, and primary peritoneal cancer in real world clinical practice.

Conditions

  • Epithelial Ovarian Cancer

Interventions

DRUG

Niraparib

Usage following drug insert is recommended

Sponsors & Collaborators

  • Ling-Ying Wu

    lead UNKNOWN

Principal Investigators

  • Lingying Wu · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-10
Primary Completion
2022-08-31
Completion
2025-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04986371 on ClinicalTrials.gov